VRANDERICK, Manon,ST-ONGE, Jean-Luc,GALLO, Michele,GERVAIS, Eric
申请号：
ES14900963
公开号：
ES2674996T3
申请日:
2014.08.29
申请国别(地区):
ES
年份:
2018
代理人:
摘要：
A solid oral dosage form comprising (a) a core comprising from about 5 mg to about 40 mg of doxylamine or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of pyridoxine or a pharmaceutically acceptable salt. Of the same； (b) an enteric coating surrounding said core； (c) a first coating containing active ingredient surrounding said enteric coating and comprising (i) from about 5 mg to about 40 mg of doxylamine or a pharmaceutically acceptable salt thereof, or (ii) from about 5 mg to about 40 mg of pyridoxine or a pharmaceutically acceptable salt thereof； and (d) a second coating containing active ingredient surrounding said first coating containing active ingredient and comprising (i) from about 5 mg to about 40 mg of doxylamine or a pharmaceutically acceptable salt thereof, or (ii) from about 5 mg to about 40 mg of pyridoxine or a pharmaceutically acceptable salt thereof； wherein said first coating containing active ingredient comprises said doxylamine or a pharmaceutically acceptable salt thereof, said second coating containing active ingredient comprises said pyridoxine or pharmaceutically acceptable salt thereof, and if said first coating containing active ingredient comprises said pyridoxine or pharmaceutically acceptable salt thereof, said second coating containing active ingredient comprises said doxylamine or a pharmaceutically acceptable salt thereof.Una forma de dosificación oral sólida que comprende (a) un núcleo que comprende de aproximadamente 5 mg a aproximadamente 40 mg de doxilamina o una sal farmacéuticamente aceptable de la misma, y de aproximadamente 5 mg a aproximadamente 40 mg de piridoxina o una sal farmacéuticamente aceptable de la misma； (b) un revestimiento entérico que rodea dicho núcleo； (c) un primer revestimiento que contiene principio activo que rodea dicho revestimiento entérico y que comprende (i) de aproximadamente 5 mg a aproximadamente 40 mg de doxilamina o una sal farmacéuticamente aceptable de la mism
